Live feed16:05:00·135dPRReleasevia QuantisnowvTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of HealthByQuantisnow·Wall Street's wire, on your screen.VTVT· vTv Therapeutics Inc.Health Care